Carfilzomib for relapsed or refractory multiple myeloma

被引：0
|
作者：
Tanimoto, Tetsuya [1 ]
Tsuda, Kenji [2 ]
Oshima, Kumi [1 ]
Mori, Jinichi [1 ]
Shimmura, Hiroaki [1 ]
机构：
[1] Tokiwa Fdn, Jyoban Hosp, Fukushima 9728322, Japan
[2] Teikyo Univ, Chiba Med Ctr, Chiba, Japan
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 01期
关键词：
BONE-DISEASE; BISPHOSPHONATE;
D O I：
10.1016/S1470-2045(17)30859-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [1] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    DRUGS, 2012, 72 (15) : 2023 - 2032
  • [2] Carfilzomib for relapsed and refractory multiple myeloma
    Groen, K.
    van de Donk, N. W. C. J.
    Stege, C. A. M.
    Zweegman, S.
    Nijhof, I. S.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2663 - 2675
  • [3] Carfilzomib for relapsed or refractory multiple myeloma reply
    Dimopoulos, Meletios A.
    Kimball, Amy S.
    LANCET ONCOLOGY, 2018, 19 (01): : E2 - E2
  • [4] The role of carfilzomib in relapsed/refractory multiple myeloma
    Yee, Andrew J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [5] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [6] Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
    Boccon-Gibod, Clementine
    Talbot, Alexis
    Le Bras, Fabien
    Frenzel, Laurent
    Royer, Bruno
    Harel, Stephanie
    Lombion, Naelle
    Belhadj, Karim
    Cuccuini, Wendy
    Arnulf, Bertrand
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E73 - E76
  • [7] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [8] Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
    Nooka, Ajay
    Gleason, Charise
    Casbourne, Daniela
    Lonial, Sagar
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 13 - 32
  • [9] ENDEAVOR: carfilzomib superior to bortezomib in relapsed and refractory multiple myeloma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (01) : 13 - 13
  • [10] Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
    Gupta, Vikas A.
    Nooka, Ajay K.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2013, 3 : 41 - 51
12345